Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Molecular Diagnostic Techniques | 8 | 2020 | 4239 | 1.65 | Why? |
Alphavirus Infections | 2 | 2017 | 68 | 1.30 | Why? |
Nucleic Acid Amplification Techniques | 6 | 2020 | 3388 | 1.16 | Why? |
RNA, Viral | 21 | 2021 | 32276 | 1.00 | Why? |
DNA Viruses | 2 | 2019 | 184 | 0.85 | Why? |
High-Throughput Nucleotide Sequencing | 6 | 2021 | 3633 | 0.82 | Why? |
Yellow fever virus | 2 | 2018 | 205 | 0.80 | Why? |
Transplantation | 1 | 2019 | 72 | 0.78 | Why? |
Viremia | 4 | 2020 | 1020 | 0.76 | Why? |
DNA Virus Infections | 1 | 2019 | 88 | 0.76 | Why? |
Yellow Fever | 2 | 2018 | 231 | 0.73 | Why? |
Reagent Kits, Diagnostic | 5 | 2021 | 2149 | 0.72 | Why? |
Clinical Laboratory Techniques | 8 | 2020 | 23402 | 0.72 | Why? |
Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.71 | Why? |
O'nyong-nyong Virus | 1 | 2017 | 9 | 0.71 | Why? |
Proviruses | 1 | 2017 | 82 | 0.69 | Why? |
Viral Envelope Proteins | 2 | 2020 | 3539 | 0.69 | Why? |
Seizures, Febrile | 1 | 2017 | 59 | 0.66 | Why? |
Alphavirus | 1 | 2017 | 90 | 0.66 | Why? |
Point-of-Care Testing | 2 | 2020 | 2782 | 0.65 | Why? |
Real-Time Polymerase Chain Reaction | 10 | 2021 | 11367 | 0.65 | Why? |
Anopheles | 1 | 2017 | 89 | 0.64 | Why? |
Poliovirus | 1 | 2017 | 109 | 0.63 | Why? |
Nucleocapsid | 1 | 2021 | 734 | 0.63 | Why? |
Metagenomics | 2 | 2019 | 823 | 0.62 | Why? |
Poliovirus Vaccine, Oral | 1 | 2017 | 95 | 0.61 | Why? |
Tumor Virus Infections | 1 | 2017 | 127 | 0.60 | Why? |
RNA Stability | 1 | 2017 | 285 | 0.59 | Why? |
BK Virus | 1 | 2017 | 135 | 0.59 | Why? |
Polyomavirus Infections | 1 | 2017 | 156 | 0.58 | Why? |
Acquired Immunodeficiency Syndrome | 1 | 2021 | 533 | 0.57 | Why? |
Urine | 1 | 2017 | 469 | 0.57 | Why? |
Dengue Virus | 4 | 2019 | 910 | 0.55 | Why? |
Papillomaviridae | 1 | 2019 | 404 | 0.55 | Why? |
Plasma | 3 | 2021 | 1809 | 0.52 | Why? |
Nasopharynx | 8 | 2021 | 10224 | 0.52 | Why? |
Papillomavirus Infections | 2 | 2019 | 861 | 0.51 | Why? |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 2021 | 13720 | 0.46 | Why? |
Mutation | 9 | 2021 | 12376 | 0.45 | Why? |
Uterine Cervical Neoplasms | 2 | 2019 | 842 | 0.44 | Why? |
Opportunistic Infections | 1 | 2017 | 602 | 0.42 | Why? |
Zika Virus | 4 | 2017 | 1924 | 0.42 | Why? |
Zika Virus Infection | 4 | 2017 | 1920 | 0.39 | Why? |
Dengue | 4 | 2019 | 1565 | 0.39 | Why? |
Point-of-Care Systems | 2 | 2020 | 2955 | 0.37 | Why? |
Ebolavirus | 1 | 2015 | 834 | 0.37 | Why? |
HIV-1 | 3 | 2018 | 3365 | 0.36 | Why? |
Viral Load | 5 | 2021 | 15850 | 0.34 | Why? |
Mass Screening | 5 | 2020 | 8005 | 0.34 | Why? |
Betacoronavirus | 15 | 2020 | 204454 | 0.34 | Why? |
Microbiota | 1 | 2017 | 1240 | 0.33 | Why? |
Antibodies, Viral | 12 | 2021 | 51949 | 0.33 | Why? |
Immunoglobulin G | 7 | 2021 | 21571 | 0.32 | Why? |
Blood Donors | 1 | 2020 | 2956 | 0.32 | Why? |
California | 4 | 2020 | 2047 | 0.32 | Why? |
Severe Dengue | 2 | 2019 | 135 | 0.31 | Why? |
Humans | 73 | 2021 | 930598 | 0.29 | Why? |
Receptors, IgG | 2 | 2020 | 578 | 0.29 | Why? |
Sensitivity and Specificity | 10 | 2021 | 22971 | 0.28 | Why? |
Viruses | 2 | 2019 | 2238 | 0.28 | Why? |
Antibody Formation | 2 | 2020 | 4038 | 0.28 | Why? |
Coronavirus Infections | 16 | 2021 | 253789 | 0.28 | Why? |
Pneumonia, Viral | 15 | 2020 | 243684 | 0.28 | Why? |
DNA, Viral | 4 | 2019 | 2521 | 0.27 | Why? |
Hemorrhagic Fever, Ebola | 1 | 2015 | 1475 | 0.27 | Why? |
Diagnostic Tests, Routine | 3 | 2021 | 2643 | 0.27 | Why? |
Multiplex Polymerase Chain Reaction | 3 | 2020 | 1439 | 0.26 | Why? |
False Negative Reactions | 2 | 2020 | 1785 | 0.26 | Why? |
Drug Resistance, Viral | 3 | 2018 | 1083 | 0.25 | Why? |
Reproducibility of Results | 5 | 2020 | 11304 | 0.24 | Why? |
Zimbabwe | 2 | 2019 | 198 | 0.23 | Why? |
Transplant Recipients | 2 | 2018 | 4982 | 0.23 | Why? |
Immunologic Tests | 2 | 2021 | 445 | 0.23 | Why? |
Isotachophoresis | 1 | 2020 | 8 | 0.22 | Why? |
Asymptomatic Infections | 1 | 2020 | 7218 | 0.22 | Why? |
Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.22 | Why? |
Immunocompromised Host | 1 | 2017 | 5150 | 0.21 | Why? |
Specimen Handling | 6 | 2021 | 6190 | 0.21 | Why? |
Adult | 30 | 2021 | 244371 | 0.20 | Why? |
Disease Transmission, Infectious | 2 | 2021 | 9044 | 0.20 | Why? |
Sequence Analysis, DNA | 3 | 2017 | 2830 | 0.20 | Why? |
DNA, Fungal | 1 | 2019 | 95 | 0.20 | Why? |
Virus Replication | 1 | 2021 | 14331 | 0.19 | Why? |
Interferon-gamma Release Tests | 1 | 2021 | 253 | 0.19 | Why? |
Genotype | 3 | 2021 | 4697 | 0.19 | Why? |
Vaginal Smears | 1 | 2019 | 89 | 0.19 | Why? |
Prostatitis | 1 | 2018 | 18 | 0.19 | Why? |
DNA-Directed RNA Polymerases | 1 | 2020 | 239 | 0.19 | Why? |
Microfluidics | 1 | 2020 | 171 | 0.19 | Why? |
Semiconductors | 1 | 2018 | 25 | 0.19 | Why? |
Stochastic Processes | 1 | 2020 | 369 | 0.19 | Why? |
Nephritis | 1 | 2018 | 39 | 0.19 | Why? |
Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 24 | 0.18 | Why? |
Lymphoma, T-Cell | 1 | 2018 | 70 | 0.18 | Why? |
Child, Preschool | 9 | 2021 | 36283 | 0.18 | Why? |
Eye Infections, Parasitic | 1 | 2017 | 9 | 0.18 | Why? |
Nicaragua | 1 | 2017 | 71 | 0.17 | Why? |
Africa, Eastern | 1 | 2017 | 90 | 0.17 | Why? |
Automation, Laboratory | 1 | 2020 | 536 | 0.17 | Why? |
DNA, Protozoan | 1 | 2017 | 77 | 0.17 | Why? |
Retrospective Studies | 11 | 2021 | 105322 | 0.17 | Why? |
Female | 30 | 2021 | 380317 | 0.17 | Why? |
Forkhead Transcription Factors | 1 | 2018 | 231 | 0.16 | Why? |
Nasopharyngeal Neoplasms | 1 | 2017 | 64 | 0.16 | Why? |
Virus Inactivation | 2 | 2017 | 1139 | 0.16 | Why? |
Time Factors | 5 | 2020 | 31397 | 0.16 | Why? |
Roseolovirus Infections | 1 | 2017 | 131 | 0.16 | Why? |
Cell-Free Nucleic Acids | 1 | 2019 | 271 | 0.16 | Why? |
Middle Aged | 23 | 2021 | 270681 | 0.16 | Why? |
Polyethylene Glycols | 1 | 2021 | 574 | 0.16 | Why? |
Cytomegalovirus | 2 | 2018 | 600 | 0.15 | Why? |
Calibration | 1 | 2017 | 307 | 0.15 | Why? |
Prospective Studies | 5 | 2021 | 43301 | 0.15 | Why? |
Herpesvirus 6, Human | 1 | 2017 | 162 | 0.15 | Why? |
Cervix Uteri | 1 | 2017 | 146 | 0.15 | Why? |
Male | 28 | 2021 | 367725 | 0.15 | Why? |
HIV Infections | 3 | 2018 | 11620 | 0.15 | Why? |
Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.15 | Why? |
CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.15 | Why? |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 526 | 0.15 | Why? |
Insect Vectors | 1 | 2017 | 227 | 0.15 | Why? |
DNA, Bacterial | 1 | 2019 | 835 | 0.15 | Why? |
Interleukins | 1 | 2021 | 762 | 0.15 | Why? |
Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.14 | Why? |
Microcephaly | 1 | 2017 | 181 | 0.14 | Why? |
Transplantation Conditioning | 1 | 2017 | 323 | 0.14 | Why? |
5' Untranslated Regions | 1 | 2017 | 375 | 0.14 | Why? |
Cytomegalovirus Infections | 2 | 2018 | 667 | 0.14 | Why? |
Blood Cell Count | 1 | 2020 | 1101 | 0.14 | Why? |
RNA Viruses | 2 | 2020 | 824 | 0.14 | Why? |
Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.14 | Why? |
Infant | 6 | 2020 | 30274 | 0.14 | Why? |
Chikungunya virus | 1 | 2017 | 339 | 0.13 | Why? |
Uveitis | 1 | 2017 | 233 | 0.13 | Why? |
Aedes | 1 | 2017 | 380 | 0.13 | Why? |
Feasibility Studies | 2 | 2021 | 3467 | 0.13 | Why? |
Area Under Curve | 1 | 2021 | 2564 | 0.13 | Why? |
Influenza A Virus, H3N2 Subtype | 1 | 2018 | 572 | 0.13 | Why? |
Herpesvirus 4, Human | 1 | 2017 | 387 | 0.13 | Why? |
Case-Control Studies | 4 | 2021 | 17671 | 0.13 | Why? |
Health Personnel | 2 | 2020 | 29646 | 0.13 | Why? |
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 2426 | 0.13 | Why? |
Child | 9 | 2020 | 70012 | 0.13 | Why? |
Vaccination | 1 | 2019 | 19050 | 0.13 | Why? |
Base Sequence | 2 | 2021 | 3581 | 0.13 | Why? |
Health Planning | 1 | 2020 | 607 | 0.12 | Why? |
Antibody-Dependent Enhancement | 1 | 2017 | 413 | 0.12 | Why? |
Pericardial Effusion | 1 | 2017 | 312 | 0.12 | Why? |
Infant, Newborn, Diseases | 1 | 2017 | 394 | 0.12 | Why? |
Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.12 | Why? |
Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
Immunoglobulin A | 3 | 2020 | 3567 | 0.12 | Why? |
Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.12 | Why? |
Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.11 | Why? |
CRISPR-Cas Systems | 1 | 2020 | 1397 | 0.11 | Why? |
Polymerase Chain Reaction | 4 | 2021 | 6740 | 0.11 | Why? |
Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
Nanotechnology | 1 | 2017 | 821 | 0.10 | Why? |
Early Detection of Cancer | 2 | 2019 | 1956 | 0.10 | Why? |
Genes, Viral | 1 | 2015 | 1428 | 0.10 | Why? |
Eye Infections, Viral | 1 | 2017 | 517 | 0.10 | Why? |
Aged | 16 | 2021 | 215776 | 0.10 | Why? |
Viral Nonstructural Proteins | 2 | 2017 | 4810 | 0.10 | Why? |
Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
Nanoparticles | 1 | 2021 | 2040 | 0.09 | Why? |
Poverty | 2 | 2019 | 2302 | 0.09 | Why? |
Mexico | 1 | 2017 | 2787 | 0.09 | Why? |
Epidemiological Monitoring | 1 | 2021 | 3493 | 0.09 | Why? |
Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
Serologic Tests | 2 | 2020 | 4359 | 0.09 | Why? |
Prevalence | 2 | 2020 | 25773 | 0.09 | Why? |
Neutralization Tests | 1 | 2021 | 6698 | 0.08 | Why? |
Temperature | 1 | 2017 | 2305 | 0.08 | Why? |
Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
Virus Shedding | 2 | 2021 | 5834 | 0.08 | Why? |
Pandemics | 16 | 2020 | 389249 | 0.08 | Why? |
Rural Population | 1 | 2019 | 2408 | 0.08 | Why? |
Young Adult | 11 | 2021 | 93724 | 0.08 | Why? |
Azithromycin | 1 | 2021 | 3943 | 0.08 | Why? |
Infant, Newborn | 4 | 2020 | 23105 | 0.07 | Why? |
Animals | 5 | 2018 | 78931 | 0.07 | Why? |
Hospitalization | 3 | 2021 | 54280 | 0.07 | Why? |
B-Lymphocytes | 1 | 2020 | 4418 | 0.07 | Why? |
Adolescent | 7 | 2020 | 86841 | 0.07 | Why? |
Ecuador | 2 | 2017 | 514 | 0.07 | Why? |
Treatment Failure | 2 | 2021 | 2106 | 0.07 | Why? |
Premature Birth | 1 | 2017 | 2151 | 0.07 | Why? |
Influenza, Human | 2 | 2021 | 10779 | 0.07 | Why? |
Protein Binding | 1 | 2021 | 11430 | 0.07 | Why? |
Genome, Viral | 3 | 2021 | 13157 | 0.07 | Why? |
Aged, 80 and over | 8 | 2020 | 88759 | 0.07 | Why? |
Computational Biology | 1 | 2019 | 4514 | 0.07 | Why? |
Cross-Sectional Studies | 3 | 2021 | 53120 | 0.07 | Why? |
Fever | 2 | 2019 | 7795 | 0.07 | Why? |
Emergency Medical Services | 1 | 2020 | 3557 | 0.06 | Why? |
Feces | 1 | 2017 | 4235 | 0.06 | Why? |
Cross Reactions | 3 | 2021 | 4374 | 0.06 | Why? |
Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
Asthma | 1 | 2021 | 4383 | 0.06 | Why? |
Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
Sequence Analysis, RNA | 2 | 2021 | 2290 | 0.06 | Why? |
DNA Fingerprinting | 1 | 2021 | 41 | 0.06 | Why? |
Immunogenetics | 1 | 2020 | 124 | 0.05 | Why? |
Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.05 | Why? |
Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.05 | Why? |
Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
Cohort Studies | 3 | 2019 | 36005 | 0.05 | Why? |
Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.05 | Why? |
Miniaturization | 1 | 2018 | 29 | 0.05 | Why? |
Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
Lymphoma, T-Cell, Peripheral | 1 | 2018 | 12 | 0.05 | Why? |
Injections, Subcutaneous | 1 | 2021 | 647 | 0.05 | Why? |
Vero Cells | 1 | 2015 | 14117 | 0.05 | Why? |
Sri Lanka | 1 | 2019 | 241 | 0.05 | Why? |
Eggs | 1 | 2018 | 43 | 0.05 | Why? |
Human T-lymphotropic virus 1 | 1 | 2018 | 52 | 0.05 | Why? |
Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
Conserved Sequence | 1 | 2021 | 751 | 0.05 | Why? |
Mycoplasma pneumoniae | 1 | 2020 | 233 | 0.05 | Why? |
Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
HIV Integrase | 1 | 2018 | 67 | 0.04 | Why? |
HIV Reverse Transcriptase | 1 | 2018 | 104 | 0.04 | Why? |
Colony Count, Microbial | 1 | 2018 | 177 | 0.04 | Why? |
Toxoplasmosis, Ocular | 1 | 2017 | 5 | 0.04 | Why? |
Incidence | 2 | 2017 | 25622 | 0.04 | Why? |
Pregnancy | 2 | 2017 | 23879 | 0.04 | Why? |
Outpatients | 2 | 2021 | 3417 | 0.04 | Why? |
Herpes Zoster Ophthalmicus | 1 | 2017 | 17 | 0.04 | Why? |
DNA Probes | 1 | 2018 | 178 | 0.04 | Why? |
Chicago | 1 | 2020 | 653 | 0.04 | Why? |
Toxoplasma | 1 | 2017 | 61 | 0.04 | Why? |
Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
Single-Blind Method | 1 | 2021 | 1283 | 0.04 | Why? |
Seasons | 2 | 2021 | 4071 | 0.04 | Why? |
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 243 | 0.04 | Why? |
Simplexvirus | 1 | 2017 | 124 | 0.04 | Why? |
United States | 2 | 2020 | 46150 | 0.04 | Why? |
Glycosylation | 1 | 2020 | 1255 | 0.04 | Why? |
Vitreous Body | 1 | 2017 | 161 | 0.04 | Why? |
Fungi | 1 | 2019 | 471 | 0.04 | Why? |
Prostate | 1 | 2018 | 283 | 0.04 | Why? |
Patient Outcome Assessment | 1 | 2020 | 707 | 0.04 | Why? |
Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.04 | Why? |
Blood Specimen Collection | 1 | 2019 | 387 | 0.04 | Why? |
Body Fluids | 1 | 2019 | 451 | 0.04 | Why? |
Adaptation, Physiological | 1 | 2018 | 359 | 0.04 | Why? |
Host-Pathogen Interactions | 1 | 2015 | 11041 | 0.04 | Why? |
Herpesvirus 3, Human | 1 | 2017 | 228 | 0.04 | Why? |
Allografts | 1 | 2018 | 761 | 0.04 | Why? |
Likelihood Functions | 1 | 2017 | 719 | 0.04 | Why? |
Diagnostic Self Evaluation | 1 | 2019 | 394 | 0.04 | Why? |
Washington | 1 | 2020 | 1722 | 0.04 | Why? |
Transplantation, Homologous | 1 | 2017 | 757 | 0.04 | Why? |
Genome, Bacterial | 1 | 2018 | 446 | 0.03 | Why? |
Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
Administration, Oral | 1 | 2021 | 2340 | 0.03 | Why? |
Herpes Simplex | 1 | 2017 | 272 | 0.03 | Why? |
Healthy Volunteers | 1 | 2019 | 1444 | 0.03 | Why? |
Chikungunya Fever | 1 | 2017 | 345 | 0.03 | Why? |
Nasal Mucosa | 1 | 2020 | 1218 | 0.03 | Why? |
Ferrets | 1 | 2018 | 1201 | 0.03 | Why? |
T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.03 | Why? |
Self Care | 1 | 2020 | 918 | 0.03 | Why? |
Antibody Affinity | 1 | 2017 | 1078 | 0.03 | Why? |
Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
Antigens, Viral | 2 | 2018 | 6298 | 0.03 | Why? |
Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.03 | Why? |
Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
Phenotype | 1 | 2021 | 4037 | 0.03 | Why? |
Bayes Theorem | 1 | 2019 | 3237 | 0.02 | Why? |
Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
Phylogeny | 2 | 2018 | 13341 | 0.02 | Why? |
Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
Bacteria | 1 | 2019 | 1897 | 0.02 | Why? |
Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
Evolution, Molecular | 1 | 2021 | 3691 | 0.02 | Why? |
Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
Blood Platelets | 1 | 2017 | 1704 | 0.02 | Why? |
Anti-HIV Agents | 1 | 2018 | 2209 | 0.02 | Why? |
Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
Risk | 1 | 2017 | 5288 | 0.02 | Why? |
Kidney | 1 | 2018 | 3648 | 0.02 | Why? |
T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
Thrombocytopenia | 1 | 2017 | 2093 | 0.02 | Why? |
Models, Statistical | 1 | 2020 | 5312 | 0.02 | Why? |
Logistic Models | 1 | 2017 | 9089 | 0.02 | Why? |
Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
Immunoglobulin M | 1 | 2020 | 9091 | 0.01 | Why? |
Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
Coronavirus | 1 | 2021 | 18339 | 0.01 | Why? |